TISSIUM Raises €30 Million in Latest Funding Round
TISSIUM, a Paris-based company specializing in innovative tissue reconstruction solutions, has successfully raised €30 million in its Series D2 funding round, announced on June 24, 2026. The company is known for developing novel solutions using its proprietary platform of biomorphic programmable polymers.
Company Overview
TISSIUM is at the forefront of creating advanced tissue reconstruction technologies. By leveraging its unique platform, the company aims to offer groundbreaking solutions that address unmet needs in the medical field. The technology is designed to enable more effective and precise tissue repair processes, potentially transforming various surgical procedures.
Leadership and Vision
The company is led by Co-founder and CEO Christophe Bancel, who has been instrumental in steering TISSIUM's strategic direction. Under his leadership, TISSIUM continues to innovate and expand its platform, focusing on enhancing the capabilities of its programmable polymers.
Funding Details
This recent financing round did not specify a lead investor and is recorded as having no named investors. However, the substantial €30 million raised is expected to significantly bolster TISSIUM's development projects and operational capabilities.
Planned Use of Funds
While specific plans for the newly acquired funds were not disclosed, it is anticipated that TISSIUM will use this capital to further advance its technology and possibly expand its market reach. Investment in research and development is likely, as the company continues to refine its polymer platform and explore new applications in tissue reconstruction.
Conclusion
With this infusion of capital, TISSIUM is well-positioned to further its mission of advancing tissue reconstruction technologies. The continued development of their biomorphic programmable polymers holds promise for significant improvements in surgical outcomes and patient care across various medical fields.